Inventiva Releases Preliminary Financial Results for H1 2026

Inventiva, a biopharmaceutical company, has disclosed its preliminary financial results for the first half of 2026. The company's cash and cash equivalents reached €166.1 million, with an additional €67.8 million in short-term deposits as of June 30, 2026. This marks an increase from December 31, 2025, figures. Operating activities consumed €48.7 million, showing a reduction from €53.7 million the previous year, influenced by an €8.8 million improvement in working capital. Research and development expenses increased to €50.1 million.

Investing activities generated €63.9 million, highlighting growth from the €24.8 million deficit in 2025, due to new short-term deposits. Financing activities provided €50.9 million, contrasted with €104.8 million in 2025, impacted by capital structure optimization and debt transactions. The lack of revenue in H1 2026 contrasts with €4.5 million from the same period in 2025. The company's cash is expected to support operations until the end of Q2 2027, contingent on further transactions.